Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child

Pediatr Hematol Oncol. 2006 Jun;23(4):339-45. doi: 10.1080/08880010600631987.

Abstract

L-Asparaginase, a major component of therapy in children with acute lymphoblastic leukemia, has been shown to induce coagulopathy by inhibiting synthesis of clot-forming and clot-inhibitory proteins. The authors report the successful use of recombinant factor VIIa in a 15-year-old girl with acute lymphoblastic leukemia who had L-asparaginase-induced intracranial hemorrhage. The present case is the first to demonstrate use of rFVIIa in L-asparaginase-induced intracranial hemorrhage in a child with acute lymphoblastic leukemia.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / adverse effects*
  • Disease-Free Survival
  • Factor VII / therapeutic use*
  • Factor VIIa
  • Female
  • Humans
  • Intracranial Hemorrhages / chemically induced*
  • Intracranial Hemorrhages / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Recombinant Proteins / therapeutic use
  • Remission Induction / methods

Substances

  • Recombinant Proteins
  • Factor VII
  • recombinant FVIIa
  • Factor VIIa
  • Asparaginase